PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28636973-4 2017 On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides. phosphoramidon 87-101 membrane metallo endopeptidase Mus musculus 41-62 28636973-4 2017 On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides. phosphoramidon 87-101 membrane metallo endopeptidase Mus musculus 64-67 28636973-4 2017 On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides. phosphoramidon 103-105 membrane metallo endopeptidase Mus musculus 41-62 28636973-4 2017 On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides. phosphoramidon 103-105 membrane metallo endopeptidase Mus musculus 64-67 26882895-15 2016 NEP inhibition with the clinically tested NEP inhibitors TO and Race resulted in significant enhancement of tumor-to-kidney ratios vs. CONTROLS: However, compared with PA, TO and its prodrug Race induced less potent increases of tumor uptake, highlighting the significance of inhibitor type, administration route, and dose for implementing a first proof-of-principle study in human. phosphoramidon 168-170 membrane metallo endopeptidase Mus musculus 0-3 26882895-1 2016 BACKGROUND: We have recently shown that treatment of mice with the neutral endopeptidase (NEP) inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of biodegradable radiopeptides. phosphoramidon 105-119 membrane metallo endopeptidase Mus musculus 90-93 26882895-1 2016 BACKGROUND: We have recently shown that treatment of mice with the neutral endopeptidase (NEP) inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of biodegradable radiopeptides. phosphoramidon 121-123 membrane metallo endopeptidase Mus musculus 90-93 26844849-6 2016 After coinjection of the NEP inhibitor, phosphoramidon (PA), the stability of [(111)In]CP04 and [(111)In-DOTA]MG0 in peripheral mouse blood increased, with an exceptional >14-fold improvement monitored for [(111)In-DOTA]MG11. phosphoramidon 56-58 membrane metallo endopeptidase Mus musculus 25-28 26844849-6 2016 After coinjection of the NEP inhibitor, phosphoramidon (PA), the stability of [(111)In]CP04 and [(111)In-DOTA]MG0 in peripheral mouse blood increased, with an exceptional >14-fold improvement monitored for [(111)In-DOTA]MG11. phosphoramidon 40-54 membrane metallo endopeptidase Mus musculus 25-28 26881775-6 2016 Accordingly, in functional experiments, CD10-A375 showed significantly greater cell proliferation in vitro and higher tumorigenicity in vivo; CD10 enzymatic inhibitors, thiorphan and phosphoramidon, significantly blocked the tumor growth of CD10-A375 in mice. phosphoramidon 183-197 membrane metallo endopeptidase Mus musculus 40-44 26881775-6 2016 Accordingly, in functional experiments, CD10-A375 showed significantly greater cell proliferation in vitro and higher tumorigenicity in vivo; CD10 enzymatic inhibitors, thiorphan and phosphoramidon, significantly blocked the tumor growth of CD10-A375 in mice. phosphoramidon 183-197 membrane metallo endopeptidase Mus musculus 142-146 26881775-6 2016 Accordingly, in functional experiments, CD10-A375 showed significantly greater cell proliferation in vitro and higher tumorigenicity in vivo; CD10 enzymatic inhibitors, thiorphan and phosphoramidon, significantly blocked the tumor growth of CD10-A375 in mice. phosphoramidon 183-197 membrane metallo endopeptidase Mus musculus 142-146 25286347-4 2014 In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA). phosphoramidon 208-222 membrane metallo endopeptidase Mus musculus 101-122 25457559-5 2015 Oral gamma-hydroxybutyrate also counteracted phosphoramidon-induced brain neprilysin inhibition and Abeta accumulation. phosphoramidon 45-59 membrane metallo endopeptidase Mus musculus 74-84 26722377-4 2016 Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic (68)Ga-/(177)Lu-JMV4168 GRPR-antagonist. phosphoramidon 70-84 membrane metallo endopeptidase Mus musculus 55-58 26722377-4 2016 Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic (68)Ga-/(177)Lu-JMV4168 GRPR-antagonist. phosphoramidon 86-88 membrane metallo endopeptidase Mus musculus 55-58 25286347-4 2014 In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA). phosphoramidon 208-222 membrane metallo endopeptidase Mus musculus 124-127 25286347-4 2014 In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA). phosphoramidon 224-226 membrane metallo endopeptidase Mus musculus 101-122 25286347-4 2014 In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA). phosphoramidon 224-226 membrane metallo endopeptidase Mus musculus 124-127 23963369-5 2013 Inhibition studies suggested that processes sensitive to insulin and phosphoramidon, which inhibit neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme, are involved not only in degradation, but also in elimination of hAbeta(1-40). phosphoramidon 69-83 membrane metallo endopeptidase Mus musculus 99-109 22387410-8 2012 OCCs are resistant to Abeta challenge in any of the conditions tested (variation of [K+]e, presence or absence of serum, or addition of the neprilysin blocker phosphoramidon). phosphoramidon 159-173 membrane metallo endopeptidase Mus musculus 140-150 21224067-4 2011 However, genetic ablation of NEP results in only modest increases (~1.5- to 2-fold) in Abeta, indicating that other thiorphan/phosphoramidon-sensitive endopeptidases are at work. phosphoramidon 126-140 membrane metallo endopeptidase Mus musculus 29-32 21224067-5 2011 Of particular interest is the NEP homolog neprilysin 2 (NEP2), which is thiorphan/phosphoramidon-sensitive and degrades Abeta. phosphoramidon 82-96 membrane metallo endopeptidase Mus musculus 30-33 21224067-10 2011 Treatment of these double-knockout mice with phosphoramidon resulted in elevations of Abeta, suggesting that yet other NEP-like Abeta-degrading endopeptidases are contributing to Abeta catabolism. phosphoramidon 45-59 membrane metallo endopeptidase Mus musculus 119-122 10749671-7 2000 The recombinant enzyme exhibited neprilysin-like peptidase activity and was efficiently inhibited by phosphoramidon and thiorphan, two inhibitors of neprilysin. phosphoramidon 101-115 membrane metallo endopeptidase Mus musculus 33-43 15993898-7 2005 Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone. phosphoramidon 72-86 membrane metallo endopeptidase Mus musculus 5-8 15993898-7 2005 Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone. phosphoramidon 72-86 membrane metallo endopeptidase Mus musculus 23-26 15993898-7 2005 Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone. phosphoramidon 72-86 membrane metallo endopeptidase Mus musculus 23-26 15993898-7 2005 Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone. phosphoramidon 72-86 membrane metallo endopeptidase Mus musculus 23-26 11447035-7 2001 Conversely, pretreatment of wild-type mice with the NEP inhibitor phosphoramidon exacerbated enteritis. phosphoramidon 66-80 membrane metallo endopeptidase Mus musculus 52-55 3539055-1 1986 The effect of the enkephalinase inhibitor phosphoramidon on the withdrawal syndrome following acute and chronic morphine-induced physical dependence in mice, was investigated. phosphoramidon 42-56 membrane metallo endopeptidase Mus musculus 18-31 8284261-1 1993 We examined the effects of captopril (an angiotensin-converting enzyme inhibitor) and phosphoramidon (a selective enkephalinase inhibitor) on Tyr-Gly-Gly production during Met-enkephalin hydrolysis in plasma samples taken from individual outbred Swiss-Webster and inbred C57BL/6J and DBA/2J mice. phosphoramidon 86-100 membrane metallo endopeptidase Mus musculus 114-127 30871262-2 2019 Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake. phosphoramidon 124-138 membrane metallo endopeptidase Mus musculus 97-107 6433386-1 1984 In order to elucidate the relationship between REM sleep and the enkephalinergic system, the effects of REM sleep deprivation (REMSD), stress and the enkephalinase inhibitor phosphoramidon on handling-induced convulsions were studied in mice. phosphoramidon 174-188 membrane metallo endopeptidase Mus musculus 150-163 33256013-2 2020 Treatment of mice with the neprilysin (NEP)-inhibitor phosphoramidon was previously shown to improve the metabolic stability and tumor uptake of biodegradable radiopeptides. phosphoramidon 54-68 membrane metallo endopeptidase Mus musculus 27-37 33256013-2 2020 Treatment of mice with the neprilysin (NEP)-inhibitor phosphoramidon was previously shown to improve the metabolic stability and tumor uptake of biodegradable radiopeptides. phosphoramidon 54-68 membrane metallo endopeptidase Mus musculus 39-42 3123978-1 1986 Enkephalinase inhibitors phosphoramidon, thiorphan or phelorphan suppressed naloxone-precipitated withdrawal symptoms in acute and chronic morphine dependent mice and rats. phosphoramidon 25-39 membrane metallo endopeptidase Mus musculus 0-13 30963606-7 2019 111 In-SB9 was more stable than 111 In-AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo. phosphoramidon 95-109 membrane metallo endopeptidase Mus musculus 68-78 30963606-7 2019 111 In-SB9 was more stable than 111 In-AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo. phosphoramidon 95-109 membrane metallo endopeptidase Mus musculus 80-83 30963606-7 2019 111 In-SB9 was more stable than 111 In-AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo. phosphoramidon 111-113 membrane metallo endopeptidase Mus musculus 68-78 30897789-5 2019 Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo. phosphoramidon 97-111 membrane metallo endopeptidase Mus musculus 137-147 30897789-5 2019 Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo. phosphoramidon 97-111 membrane metallo endopeptidase Mus musculus 149-152 30897789-5 2019 Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo. phosphoramidon 113-115 membrane metallo endopeptidase Mus musculus 137-147 30897789-5 2019 Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo. phosphoramidon 113-115 membrane metallo endopeptidase Mus musculus 149-152 30871262-2 2019 Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake. phosphoramidon 124-138 membrane metallo endopeptidase Mus musculus 109-112 30871262-2 2019 Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake. phosphoramidon 140-142 membrane metallo endopeptidase Mus musculus 97-107 30871262-2 2019 Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake. phosphoramidon 140-142 membrane metallo endopeptidase Mus musculus 109-112 29556947-5 2018 A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA). phosphoramidon 134-148 membrane metallo endopeptidase Mus musculus 95-116 29556947-5 2018 A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA). phosphoramidon 134-148 membrane metallo endopeptidase Mus musculus 118-121 29556947-5 2018 A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA). phosphoramidon 150-152 membrane metallo endopeptidase Mus musculus 95-116 29556947-5 2018 A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA). phosphoramidon 150-152 membrane metallo endopeptidase Mus musculus 118-121 29664606-7 2018 Coinjection of the radioconjugates with the neprilysin (NEP)-inhibitor phosphoramidon led to full stabilization of 111In/177Lu-SB3 in peripheral mouse blood and resulted in markedly enhanced radiolabel uptake in the PC-3 tumors. phosphoramidon 71-85 membrane metallo endopeptidase Mus musculus 44-54 29664606-7 2018 Coinjection of the radioconjugates with the neprilysin (NEP)-inhibitor phosphoramidon led to full stabilization of 111In/177Lu-SB3 in peripheral mouse blood and resulted in markedly enhanced radiolabel uptake in the PC-3 tumors. phosphoramidon 71-85 membrane metallo endopeptidase Mus musculus 56-59